Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421352 | 0.87 | ALDH1A1 (0.39) | L3MBTL1LMNAPOLBGAAMAPT | |
| SCHEMBL4424169 | 0.79 | ALDH1A1 (0.49) | LMNAPOLBGAATSHRMAPK1 | |
| SCHEMBL10068738 | 0.78 | HCRTR1 (0.38) | LMNAGAAMAPTALDH1A1 | |
| SCHEMBL13403436 | 0.78 | HTT (0.41) | L3MBTL1LMNAATMGAAMAPT | |
| SCHEMBL4412254 | 0.77 | L3MBTL1 (0.49) | L3MBTL1LMNAPOLBPKMMAPT | |
| SCHEMBL4410209 | 0.75 | POLB (0.45) | L3MBTL1LMNAPOLBADRA2CATM | |
| SCHEMBL372408 | 0.69 | KMT2A (0.50) | L3MBTL1LMNAATMGAAMAPK1 | |
| Iodide SCHEMBL11170910 | 0.69 | GAA (0.52) | L3MBTL1LMNAPOLBADRA2CATM | |
| SCHEMBL2342698 | 0.68 | ADRA2C (0.64) | L3MBTL1LMNAPOLBADRA2CATM | |
| SCHEMBL30327328 | 0.68 | ADRA2C (0.64) | L3MBTL1LMNAPOLBADRA2CATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572791-B2 | Therapeutic morpholino-substituted compounds | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-12-18 | — | — | US | disclosed |
| US-20080206312-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-08-28 | — | — | US | disclosed |
| US-7405211-B2 | Using 2-morpholinyl-4H-pyrido(1,2-a)pyrimidin-4-one; enzyme inhibitors; antithrombotic agents ; restenosis; atherosclerosis; antihistamines; chronic obsessive pulminary disease; autoimmune diseases; anticancer agents; antiinflammatory agents | ASTRAZENECA AB (SE) | 2008-07-29 | — | — | US | disclosed |
| EP-1857443-A2 | Therapeutic morpholino-substituted compounds | AstraZeneca AB (SE) | 2007-11-21 | — | — | EP | disclosed |
| EP-1257537-B1 | THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| US-6977255-B2 | Therapeutic morpholino-substituted compounds | KINACIA PTY. LTD. (AU) | 2005-12-20 | — | — | US | disclosed |
| US-20050085471-A1 | Therapeutic morpholino-substituted compounds | KINACIA PTY LTD. | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085471-A1 | Therapeutic morpholino-substituted compounds | PIK3CA, PTK2, PDPK1 | L3MBTL1 1690/4885LMNA 4199/4885POLB 1389/4885 |
| US-20080206312-A1 | Therapeutic Morpholino-Substituted Compounds | PIK3CA, PTK2, PDPK1 | L3MBTL1 1693/4885LMNA 4183/4885POLB 1363/4885 |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | PIK3CA, PTK2, PDPK1 | L3MBTL1 1693/4885LMNA 4183/4885POLB 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.